News

October 29, 2019

Tempus Announces the Appointment of Scott Gottlieb, MD, to Its Board Of Directors

Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, today announced that Dr. Scott Gottlieb, MD, has joined its Board of Directors. Dr. Gottlieb will serve as an advisor to Tempus and its leadership team, leveraging his vast experience as a...

September 30, 2019

Nature Biotechnology Study Reveals that Tempus’ xT Platform Increases Cancer Patients’ Personalized Therapeutic Opportunities

Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, today published a study in Nature Biotechnology, one of the industry’s leading peer-reviewed, scientific journals, surrounding its xT platform. The study, which focuses on 500 patient samples across diverse tumor types ana...

September 17, 2019

Geisinger and Tempus Announce Collaboration to Develop Cardiology Diagnostic and Prognostic Tools Using Artificial Intelligence

Geisinger announced today a new multi-year partnership with Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. The collaboration aims to use the power of machine learning and artificial intelligence to build new precision medicine tools for cardiology that will enable...

September 3, 2019

Tempus Expands Its Management Team with the Appointment of Lauren Silvis as Senior Vice President of External Affairs

Tempus, a technology company advancing precision medicine through the collection and analysis of molecular and clinical data at scale, announced today the appointment of Lauren Silvis as its Senior Vice President of External Affairs. Silvis will oversee regulatory, public policy and government affairs, operating from Tempus’ office to...

August 29, 2019

Tempus Announces New Subscription Service for Pharma, Biotech and Academic Researchers

Tempus, a technology company advancing precision medicine through the collection and analysis of molecular and clinical data at scale, announced today that it is providing its de-identified datasets via a data subscription, enabling researchers to leverage unique, longitudinally-updated clinical and molecular data at scale, which will help accelerate...

August 22, 2019

Tempus Expands Leadership Team with the Appointment of Joel Dudley, PhD, as Senior Vice President of Research

Tempus, a technology company advancing precision medicine through the collection and analysis of molecular and clinical data at scale, announces the appointment of Joel Dudley, PhD, as its Senior Vice President of Research. In his role, Dr. Dudley is responsible for leading Tempus’s research and development efforts...

July 31, 2019

Groupon Made Eric Lefkofsky A Billionaire—His Cancer-Fighting Startup Is Worth Far More

Forbes | Noah Kirsch & Michela Tindera Eric Lefkofsky hasn’t taken a science class since college. But as he meanders through the Chicago lab of Tempus, his medical startup, he presents an air of expertise. “One thing you can see right off the bat is the purple staining of this cell,” he says, pointing to the pathology slid...

June 11, 2019

Tempus and Leidos Biomedical Research Inc. Launch Effort to Enhance The Cancer Genome Atlas

Tempus, a technology company advancing precision medicine through the collection and analysis of molecular and clinical data at scale announced today that it was selected by Leidos Biomedical Research Inc. (Leidos Biomed) to abstract and structure follow-up clinical data for The Cancer Genome Atlas (TCGA) Project for submission...

June 3, 2019

Tempus Announces (TIME) Trial Service, a New Integrated Molecular Evaluation that Leverages Artificial Intelligence to Rapidly Match Cancer Patients to Clinical Trials

Tempus, a technology company advancing precision medicine through the collection and analysis of molecular and clinical data at scale, announced today a new service, Tempus Integrated Molecular Evaluation (TIME) Trial, which aims to increase clinical trial enrollment and participation for cancer patients who are treated in both the...

May 30, 2019

Tempus Announces $200 Million in Series F Financing

Tempus, a leading technology company advancing precision medicine through the collection and analysis of molecular and clinical data, announced today an additional $200M financing at a value of $3.1 billion dollars. The investors include Baillie Gifford, Franklin Templeton, NEA, Novo Holdings, Revolution Growth, and funds and accounts managed by...

Show More